Brief: Eiger's Single-Dose Peginterferon Lambda For Covid-19 Reduced Risk Of Hospitalization Or Er Visits By 50% In A Predominantly Vaccinated Population In Phase 3 Together Study

Eiger Biopharmaceuticals

17/03/2022 13:52

March 17 (Reuters) - Eiger BioPharmaceuticals Inc  EIGR.O :
    * EIGER'S SINGLE-DOSE PEGINTERFERON LAMBDA FOR COVID-19
REDUCED
RISK OF HOSPITALIZATION OR ER VISITS BY 50% IN A PREDOMINANTLY
VACCINATED POPULATION IN PHASE 3 TOGETHER STUDY
    * EIGER BIOPHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED
ACROSS
MULTIPLE SARS-COV-2 VARIANTS, INCLUDING OMICRON
    * EIGER BIOPHARMACEUTICALS INC - PLANS TO SUBMIT DATA TO FDA
FOR
EMERGENCY USE AUTHORIZATION FOR PHASE 3 TOGETHER STUDY

Source text for Eikon:  ID:nPn2r4TqCa 
Further company coverage:  EIGR.O 

 ((Reuters.Briefs@thomsonreuters.com;))